Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...

Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and safety of COVID-19 vaccines for young children.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

Photo: Adobe Stock Despite the CDC’s move to kick the COVID-19 vaccine off recommended immunization schedules for children ...